Annual CFI
-$2.92 B
+$2.84 B+49.24%
01 December 2023
Summary:
Sinovac Biotech annual cash flow from investing activities is currently -$2.92 billion, with the most recent change of +$2.84 billion (+49.24%) on 01 December 2023. During the last 3 years, it has fallen by -$2.72 billion (-1328.10%). SVA annual CFI is now -974704233.33% below its all-time high of -$300.00, reached on 01 April 2002.SVA Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
N/A
01 June 2024
Summary:
Sinovac Biotech quarterly cash flow from investing activities is not available.SVA Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
N/A
01 June 2024
Summary:
Sinovac Biotech TTM cash flow from investing activities is not available.SVA TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SVA Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -1328.1% | - | - |
| 5 y5 years | -10000.0% | - | - |
SVA Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1328.1% | +49.2% | ||||
| 5 y | 5 years | <-9999.0% | +49.2% | ||||
| alltime | all time | <-9999.0% | +49.2% |
Sinovac Biotech Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$2.92 B(-49.2%) | - | - |
| Dec 2022 | -$5.76 B(+90.5%) | - | - |
| Dec 2021 | -$3.02 B(+1376.7%) | - | - |
| Dec 2020 | -$204.76 M(+382.3%) | -$152.15 M(+400.7%) | -$204.76 M(+141.2%) |
| Sept 2020 | - | -$30.39 M(-36.5%) | -$84.90 M(+45.5%) |
| June 2020 | - | -$47.87 M(-286.6%) | -$58.34 M(+259.1%) |
| Mar 2020 | - | $25.65 M(-179.4%) | -$16.25 M(-61.7%) |
| Dec 2019 | -$42.45 M(+68.1%) | -$32.30 M(+744.3%) | -$42.45 M(+253.8%) |
| Sept 2019 | - | -$3.83 M(-33.8%) | -$12.00 M(-58.2%) |
| June 2019 | - | -$5.78 M(+937.0%) | -$28.73 M(+18.4%) |
| Mar 2019 | - | -$557.00 K(-69.7%) | -$24.28 M(-3.9%) |
| Dec 2018 | -$25.26 M(+112.3%) | -$1.84 M(-91.1%) | -$25.26 M(+7.9%) |
| Sept 2018 | - | -$20.56 M(+1461.3%) | -$23.42 M(+719.2%) |
| June 2018 | - | -$1.32 M(-14.6%) | -$2.86 M(+85.4%) |
| Mar 2018 | - | -$1.54 M(-65.1%) | -$1.54 M(-86.9%) |
| Dec 2017 | -$11.90 M(+1.0%) | - | - |
| Dec 2016 | -$11.78 M(+160.8%) | -$4.42 M(+22.4%) | -$11.78 M(+38.6%) |
| Sept 2016 | - | -$3.61 M(+238.7%) | -$8.50 M(+56.9%) |
| June 2016 | - | -$1.07 M(-60.2%) | -$5.42 M(+0.0%) |
| Mar 2016 | - | -$2.68 M(+134.6%) | -$5.41 M(+19.9%) |
| Dec 2015 | -$4.51 M(-59.0%) | -$1.14 M(+116.3%) | -$4.51 M(-36.1%) |
| Sept 2015 | - | -$528.00 K(-50.4%) | -$7.07 M(-13.4%) |
| June 2015 | - | -$1.06 M(-40.3%) | -$8.16 M(-22.8%) |
| Mar 2015 | - | -$1.78 M(-51.8%) | -$10.58 M(-3.8%) |
| Dec 2014 | -$11.00 M(+112.6%) | -$3.70 M(+127.6%) | -$11.00 M(+21.6%) |
| Sept 2014 | - | -$1.62 M(-53.3%) | -$9.05 M(+4.9%) |
| June 2014 | - | -$3.48 M(+57.8%) | -$8.63 M(+65.3%) |
| Mar 2014 | - | -$2.20 M(+26.7%) | -$5.22 M(+0.9%) |
| Dec 2013 | -$5.18 M | -$1.74 M(+44.3%) | -$5.18 M(-40.1%) |
| Sept 2013 | - | -$1.21 M(+1573.6%) | -$8.65 M(-26.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | - | -$72.00 K(-96.7%) | -$11.76 M(-23.4%) |
| Mar 2013 | - | -$2.16 M(-58.5%) | -$15.35 M(-5.0%) |
| Dec 2012 | -$16.15 M(+17.1%) | -$5.21 M(+20.5%) | -$16.15 M(-211.2%) |
| Sept 2012 | - | -$4.32 M(+18.1%) | $14.53 M(+135.3%) |
| June 2012 | - | -$3.66 M(+23.6%) | $6.17 M(-139.6%) |
| Mar 2012 | - | -$2.96 M(-111.6%) | -$15.60 M(+13.1%) |
| Dec 2011 | -$13.79 M(-28.3%) | $25.47 M(-300.9%) | -$13.79 M(-68.9%) |
| Sept 2011 | - | -$12.67 M(-50.2%) | -$44.34 M(+35.3%) |
| June 2011 | - | -$25.43 M(+2101.8%) | -$32.78 M(+200.4%) |
| Mar 2011 | - | -$1.15 M(-77.3%) | -$10.91 M(-43.3%) |
| Dec 2010 | -$19.24 M(+64.6%) | -$5.08 M(+355.7%) | -$19.24 M(-14.0%) |
| Sept 2010 | - | -$1.11 M(-68.7%) | -$22.38 M(-2.6%) |
| June 2010 | - | -$3.56 M(-62.5%) | -$22.98 M(+13.9%) |
| Mar 2010 | - | -$9.49 M(+15.5%) | -$20.17 M(+72.5%) |
| Dec 2009 | -$11.69 M(+195.3%) | -$8.21 M(+377.9%) | -$11.69 M(+181.4%) |
| Sept 2009 | - | -$1.72 M(+129.0%) | -$4.16 M(+36.3%) |
| June 2009 | - | -$750.50 K(-25.8%) | -$3.05 M(+17.6%) |
| Mar 2009 | - | -$1.01 M(+49.7%) | -$2.59 M(-34.5%) |
| Dec 2008 | -$3.96 M(+62.1%) | -$675.50 K(+10.2%) | -$3.96 M(+20.6%) |
| Sept 2008 | - | -$612.70 K(+108.8%) | -$3.28 M(+22.9%) |
| June 2008 | - | -$293.40 K(-87.7%) | -$2.67 M(+12.3%) |
| Mar 2008 | - | -$2.38 M | -$2.38 M |
| Dec 2007 | -$2.44 M(+329.0%) | - | - |
| Dec 2006 | -$569.30 K(-88.3%) | - | - |
| Dec 2005 | -$4.88 M(+60.1%) | - | - |
| Dec 2004 | -$3.05 M(+318.2%) | - | - |
| Dec 2003 | -$729.20 K(>+9900.0%) | - | - |
| Apr 2002 | -$300.00(-83.3%) | - | - |
| Apr 2001 | -$1800.00(-96.2%) | - | - |
| Apr 2000 | -$47.30 K | - | - |
FAQ
- What is Sinovac Biotech annual cash flow from investing activities?
- What is the all time high annual CFI for Sinovac Biotech?
- What is the all time high quarterly CFI for Sinovac Biotech?
- What is the all time high TTM CFI for Sinovac Biotech?
What is Sinovac Biotech annual cash flow from investing activities?
The current annual CFI of SVA is -$2.92 B
What is the all time high annual CFI for Sinovac Biotech?
Sinovac Biotech all-time high annual cash flow from investing activities is -$300.00
What is the all time high quarterly CFI for Sinovac Biotech?
Sinovac Biotech all-time high quarterly cash flow from investing activities is $25.65 M
What is the all time high TTM CFI for Sinovac Biotech?
Sinovac Biotech all-time high TTM cash flow from investing activities is $14.53 M